Intelligence Feed event · Equity · 2026-09-12

    Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1

    Question

    Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1

    Direct answer

    Eli Lilly generated $2.6 billion from its Immunology division in the first half of 2026, marking a 9% year-over-year expansion. While the business currently represents 6.1% of aggregate firm revenue, new launches including Ebglyss and Omvoh are scaling commercial availability. Strategic acquisitions of DICE, Morphic, and Merida provide additional early- and mid-stage clinical assets to insulate long-term growth from GLP-1 patent horizons.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-revenue-reaches-2-6b-in-h1-2026-to-diversify-beyond-glp-1-8dbac1

    EQUITY
    Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1
    Eli Lilly generated $2.6 billion from its Immunology division in the first half of 2026, marking a 9% year-over-year expansion. While the business currently represents 6.1% of aggregate firm revenue, new launches including Ebglyss and Omvoh are scaling commercial availability. Strategic acquisitions of DICE, Morphic, and Merida provide additional early- and mid-stage clinical assets to insulate long-term growth from GLP-1 patent horizons.
    LLY
    Impact
    64
    SEP 12
    SIG
    85%
    LLY
    Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1
    Eli Lilly generated $2.6 billion from its Immunology division in the first half of 2026, marking a 9% year-over-year expansion. While the business currently represents 6.1% of aggregate firm revenue, new launches including Ebglyss and Omvoh are scaling commercial availability. Strategic acquisitions of DICE, Morphic, and Merida provide additional early- and mid-stage clinical assets to insulate long-term growth from GLP-1 patent horizons.
    → Pipeline diversification into immunology reduces terminal cash-flow reliance on GLP-1 franchise pricing for LLY.
    Impact
    Eli Lilly generated $2.6 billion from its Immunology division in the first half of 2026, marking a 9% year-over-year expansion. While the business currently represents 6.1% of aggregate firm revenue, new launches including Ebglyss and Omvoh are scaling commercial availability. Strategic acquisitions of DICE, Morphic, and Merida provide additional early- and mid-stage clinical assets to insulate long-term growth from GLP-1 patent horizons.
    Affected
    LLY
    Transmission
    Pipeline diversification into immunology reduces terminal cash-flow reliance on GLP-1 franchise pricing for LLY.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYrevenue diversification and biopharma pipeline expansionUp1-3mImmunology revenue up 9% YoY to $2.6B in H1 2026 with new products scaling.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month